377 related articles for article (PubMed ID: 24222095)
1. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.
Cohen DE; Fisher EA
Semin Liver Dis; 2013 Nov; 33(4):380-8. PubMed ID: 24222095
[TBL] [Abstract][Full Text] [Related]
2. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
3. Dyslipidemia in patients with nonalcoholic fatty liver disease.
Chatrath H; Vuppalanchi R; Chalasani N
Semin Liver Dis; 2012 Feb; 32(1):22-9. PubMed ID: 22418885
[TBL] [Abstract][Full Text] [Related]
4. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients.
Cassader M; Gambino R; Musso G; Depetris N; Mecca F; Cavallo-Perin P; Pacini G; Rizzetto M; Pagano G
Lipids; 2001 Oct; 36(10):1117-24. PubMed ID: 11768156
[TBL] [Abstract][Full Text] [Related]
5. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.
Siddiqui MS; Fuchs M; Idowu MO; Luketic VA; Boyett S; Sargeant C; Stravitz RT; Puri P; Matherly S; Sterling RK; Contos M; Sanyal AJ
Clin Gastroenterol Hepatol; 2015 May; 13(5):1000-8.e3. PubMed ID: 25311381
[TBL] [Abstract][Full Text] [Related]
6. Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: A focus on atherogenic dyslipidemia.
Amor AJ; Pinyol M; Solà E; Catalan M; Cofán M; Herreras Z; Amigó N; Gilabert R; Sala-Vila A; Ros E; Ortega E
J Clin Lipidol; 2017; 11(2):551-561.e7. PubMed ID: 28502513
[TBL] [Abstract][Full Text] [Related]
7. Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males.
Peng K; Mo Z; Tian G
Am J Med Sci; 2017 Mar; 353(3):236-241. PubMed ID: 28262209
[TBL] [Abstract][Full Text] [Related]
8. New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
Taskinen MR; Borén J
Atherosclerosis; 2015 Apr; 239(2):483-95. PubMed ID: 25706066
[TBL] [Abstract][Full Text] [Related]
9. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk.
Alkhouri N; Tamimi TA; Yerian L; Lopez R; Zein NN; Feldstein AE
Dig Dis Sci; 2010 Sep; 55(9):2644-50. PubMed ID: 19960252
[TBL] [Abstract][Full Text] [Related]
10. Lipid targets during statin treatment in dyslipidemic patients affected by nonalcoholic fatty liver disease.
Maroni L; Guasti L; Castiglioni L; Marino F; Contini S; Macchi V; De Leo A; Gaudio G; Tozzi M; Grandi AM; Cosentino M; Venco A
Am J Med Sci; 2011 Nov; 342(5):383-7. PubMed ID: 21629037
[TBL] [Abstract][Full Text] [Related]
11. Fatty liver, insulin resistance, and dyslipidemia.
Adiels M; Taskinen MR; Borén J
Curr Diab Rep; 2008 Feb; 8(1):60-4. PubMed ID: 18367000
[TBL] [Abstract][Full Text] [Related]
12. Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: Jinchang cohort study.
Ren XY; Shi D; Ding J; Cheng ZY; Li HY; Li JS; Pu HQ; Yang AM; He CL; Zhang JP; Ma YB; Zhang YW; Zheng TZ; Bai YN; Cheng N
Lipids Health Dis; 2019 Feb; 18(1):47. PubMed ID: 30744645
[TBL] [Abstract][Full Text] [Related]
13. [Pathophysiology of NAsh/NAFLD associated with high levels of serum triglycerides].
Ogawa Y; Imajo K; Yoneda M; Nakajima A
Nihon Rinsho; 2013 Sep; 71(9):1623-9. PubMed ID: 24205725
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis.
DeFilippis AP; Blaha MJ; Martin SS; Reed RM; Jones SR; Nasir K; Blumenthal RS; Budoff MJ
Atherosclerosis; 2013 Apr; 227(2):429-36. PubMed ID: 23419204
[TBL] [Abstract][Full Text] [Related]
15. Increased ABCA1 (ATP-Binding Cassette Transporter A1)-Specific Cholesterol Efflux Capacity in Schizophrenia.
Luquain-Costaz C; Kockx M; Anastasius M; Chow V; Kontush A; Jessup W; Kritharides L
Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2728-2737. PubMed ID: 32907370
[TBL] [Abstract][Full Text] [Related]
16. Interpreting lipoproteins in nonalcoholic fatty liver disease.
Nemes K; Åberg F
Curr Opin Lipidol; 2017 Aug; 28(4):355-360. PubMed ID: 28441156
[TBL] [Abstract][Full Text] [Related]
17. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
18. Dyslipidemia in nonalcoholic fatty liver disease.
Amor AJ; Perea V
Curr Opin Endocrinol Diabetes Obes; 2019 Apr; 26(2):103-108. PubMed ID: 30694825
[TBL] [Abstract][Full Text] [Related]
19. A meal high in saturated fat evokes postprandial dyslipemia, hyperinsulinemia, and altered lipoprotein expression in obese children with and without nonalcoholic fatty liver disease.
Mager DR; Mazurak V; Rodriguez-Dimitrescu C; Vine D; Jetha M; Ball G; Yap J
JPEN J Parenter Enteral Nutr; 2013 Jul; 37(4):517-28. PubMed ID: 23223552
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated lipid metabolism links NAFLD to cardiovascular disease.
Deprince A; Haas JT; Staels B
Mol Metab; 2020 Dec; 42():101092. PubMed ID: 33010471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
